The recent ban on HHC in France has paved the way for the emergence of other cannabinoids, notably VMAC. This legal cannabis derivative is intriguing and sparking public curiosity about its therapeutic potential and effects compared to the established CBD market.
VMAC: A New Cannabis Derivative
Following the ban on HHC in France in June 2023, companies specializing in legal cannabis have had to innovate to offer alternatives that comply with the law and satisfy their customers. This is the case with the White Rabbit brand, which now offers VMAC as a substitute for HHC to its customers. It is a much less well-known cannabinoid focused on relaxation and well-being, without the “high” or psychoactive effects associated with THC. Many other cannabinoids are available.In addition to VMAC, other molecules derived from cannabis exist, some of which are authorized for sale in France:
CBD (cannabidiol): one of the most widely used components for its anti-inflammatory, analgesic, and relaxing properties.
CBG (cannabigerol): a non-psychoactive cannabinoid with anti-inflammatory, antibacterial, and antispasmodic effects.
CBN (cannabinol): a molecule whose properties are being studied for the treatment of insomnia and stress.
- THCV (tetrahydrocannabivarin): a cannabinoid that affects satiety, energy, and likely has interesting anxiolytic potential.
- VMAC vs. CBD: Notable Differences
- Therapeutic Potential
- VMAC is considered to have relaxing and soothing effects, particularly for those suffering from pain or inflammation, as well as for people with anxiety disorders. This contrasts with CBD, which has already proven its therapeutic efficacy in numerous medical conditions ranging from anxiety to neurodegenerative diseases.
Legality
HHC was withdrawn from the market due to its classification as a narcotic.
Other cannabis derivatives, such as VMAC and CBD, remain legal in France as long as they do not contain more than 0.2% THC. However, it is important to note that legislation can change rapidly due to the lack of clear regulations concerning these substances and increasing public pressure to clarify their legal status. Risk of confusion
Consumers often encounter confusion between different cannabinoids (CBD, VMAC, THCV, etc.). This confusion can arise because some products continue to be marketed as “HHC” when they are actually based on VMAC or other legal derivatives. To avoid misunderstandings and mistakes, it is essential to be aware of the specific characteristics of each substance and to pay close attention to the information on the packaging.
Future Outlook
The market for cannabinoids such as VMAC and CBD is experiencing rapid and consistent growth, particularly in the wellness and healthcare sectors. However, the lack of a clear and stable regulatory framework poses a major challenge for businesses and consumers in this sector.
In conclusion, while VMAC can be considered an interesting alternative to CBD, further research is needed to better understand its medical and therapeutic potential and to inform professionals and consumers about this still relatively unknown molecule. Sources
- https://www.newsweed.fr/vmac-substitut-hhc/
- https://www.ouest-france.fr/societe/cannabis/thcv-h4cbd-ces-molecules-derivees-du-cannabis-qui-remplacent-deja-le-hhc-579b9a48-0b93-11ee-b114-e17c9aa1db34
- https://www.cnews.fr/sante/2023-05-29/cbd-hhc-h4cbd-cbg-cbn-tout-comprendre-ces-derives-du-cannabis-1359859
- https://ici.radio-canada.ca/nouvelle/1950780/teca-canna-origami-extraction-gabriel-belanger-alexandre-gagne-haschich-resine-concentre
